DAXOR CORP (DXR): Submission of Matters to a Vote of Security Holders

DAXOR CORP (DXR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000027367 0000027367 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Event · Shareholder vote
Original reporting
Published Jun 24, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$DXR
Neutral
high confidence
Mentioned
$DXR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DXRNeutralLow
01

Why it matters

Director elections were approved with specified vote counts; shareholders also ratified Bush & Associates, CPA as independent registered public accounting firm. No new business terms, clinical/regulatory milestones, or financial guidance are included.

02

Market read

This is a procedural governance disclosure; it mainly updates corporate control/auditor status rather than changing fundamentals.

03

What to watch

The only potentially actionable item is auditor ratification, which is typically procedural and rarely changes near-term risk/earnings expectations.

Relevance 6/10Novelty 2/10Timing: post-close/after-hours following the June 23 annual meeting vote results

Background

The SEC Form 8-K (Item 5.07) summarizes matters voted on at Daxor’s June 23, 2026 annual meeting.

Company-level read

Ticker impact

$DXRNeutralHigh confidence
Context

Daxor’s 8-K reports June 23, 2026 annual meeting results, including director elections and ratification of its independent auditor.

Expected impact

Low likelihood of a sustained price move based solely on this 8-K; any reaction would be limited to governance/auditor housekeeping.

Evidence & confidence

Item 5.07 only summarizes voting outcomes (board elections and auditor ratification) without new operating or financial datapoints.

Market effects

Minimal; no change to medical diagnostics/biotech competitive landscape is disclosed.

Minimal; Nasdaq-listed microcap governance update only.

Minimal; no cross-border transaction or regulatory action mentioned.

Counterpoint

Traders could still monitor for follow-on filings (e.g., subsequent 10-Q/8-K) if board changes signal strategic shifts, but this specific document does not provide that signal.

Key entities

  • Daxor Corporation

    Nasdaq-listed medical instrumentation/biotechnology company; subject of the 8-K voting results.

  • Bush & Associates, CPA

    Independent registered public accounting firm ratified by shareholders at the annual meeting.

Related articles

$DXRMedAI 8/10

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

$DXRMedAI 8/10

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

$ITGRMed

Integer noteholders receive conversion terms following merger

Integer Holdings Corporation completed its merger with Armstrong Bidco Inc., triggering conversion rights for holders of its 2.125% Convertible Senior Notes due 2028 and 1.875% Convertible Senior Notes due 2030. Noteholders can convert their securities until January 8, 2027, receiving enhanced rates during the make-whole period. The company is not required to repurchase the notes due to the merger's cash-only nature.

$CNTYMed

Century Casinos, Inc. Announces Restatement of Previously Issued Financial Statements and Preliminary Third Quarter 2026 Financial Results

Century Casinos (CNTY) will restate financial statements due to accounting errors related to a minority interest in the Nugget Casino Resort. Preliminary Q3 2026 results show $60.2M in cash, $158.4M in revenue, and $20.7M in earnings. The company also announced the sale of its Canadian operations. The restatement may affect internal controls and financial reporting.